New Filings At The EMA
Executive Summary
New medicines under evaluation at the European Medicines Agency.
You may also be interested in...
Alexion’s Soliris Successor Among New Drugs Under EMA Review
Alexion Pharmaceuticals’ successor to its blockbuster Soliris is among the new investigational drugs being reviewed for EU marketing approval.
Celgene, Agios Drug Enasidenib Among New Filings At EMA
Enasidenib, which last year became the first US-approved treatment for relapsed or refractory acute myeloid leukemia with an IDH2 mutation, is among a new crop of products being reviewed for marketing approval in the EU.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.